Johnson & Johnson’s Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.

In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.

The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.

Related Video

U.K. Prime Minister Boris Johnson announced a four-week extension to the country's Covid-19 restrictions Monday as the country deals with an increase in Delta variant infections. WSJ’s Jason Douglas explains what that could mean for the global effort to contain the virus. Photo: Henry Nicholls/Reuters (Video from 6/14/2021) The Wall Street Journal Interactive Edition

How well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.

Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots from Pfizer Inc. and its partner BioNTech SE and from Moderna Inc.

The new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.

J&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.

J&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.

The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries, including the U.S.

The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.

Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.

So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.

Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech and AstraZeneca PLC offered substantial protection from the Delta variant against severe cases of Covid-19 and hospitalization.

England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.

J&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.

J&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.

Production of the spike protein, in turn, prompts the immune system to develop molecular defenses against the coronavirus.

In its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.

Overall, however, it was highly effective in places where variants were spreading during the trial.

J&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.

The study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.

Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.

The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.

The U.S. Food and Drug Administration authorized J&J’s shot in February.

In April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.

The authorities lifted the pause shortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.

Write to Laura Cooper at laura.cooper@wsj.com

Corrections & Amplifications
Johnson & Johnson’s Covid-19 vaccine was 66% effective protecting against moderate to severe disease and 85% effective against severe disease. An earlier version of this article incorrectly said J&J’s vaccine was 66% effective protecting against severe disease. (Corrected on July 1)